LDS/Medical Tests/Myosin regulatory light chain 2 (MYL2) Gene Mutation Analysis

Myosin regulatory light chain 2 (MYL2) Gene Mutation Analysis

The MYL2 gene is located on the long (q) arm of chromosome 12 at position 24.11 and encodes myosin regulatory light chain 2 (MLC-2) protein also known as ventricular myosin light chain-2 (MLC-2v). MLC-2v is a 19-KDa protein composed of 166 amino acids that belong to a highly conserved helix-loop-helix region (termed EF hands) of Ca2+-binding superfamily and is expressed in ventricular myocardium. MLC-2v interacts with the neck/tail region of the muscle thick filament protein myosin to regulate myosin motility and function. It plays an important role in cross-bridge cycling kinetics and cardiac muscle contraction. Moreover, MLC-2v plays an essential role in early embryonic cardiac development and function and is one of the earliest markers of ventricular specification. Mutations in MYL2 have been associated with inherited hypertrophic cardiomyopathy (HCM). Familial HCM is typically inherited in an autosomal dominant manner and is characterized by unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. The majority of HCM patients are asymptomatic. Only about 25% develop symptom such as dyspnea, syncope, collapse, palpitations, and chest pain. The disorder has inter- and intra-familial variability ranging from benign cases to malignant forms with a high risk of cardiac failure and sudden cardiac death. HCM is the most common cause of sudden cardiac death in young people and has a prevalence of 1:500 in the general adult population. Rarely, patients present a variant of familial hypertrophic cardiomyopathy, characterized by mid-left ventricular chamber thickening. The majority of the mutations in HCM are missense, insertion/deletion and frame-shift mutations. MYL2 mutations account for < 3% of inherited HCM.
  • As an aid in diagnosis of familial hypertrophic cardiomyopathy and dilated cardiomyopathy
  • Carrier screening for relatives and those with the family history
  • Prenatal carrier screening for those with the family history
Mutation or pathogenic variant in MYL2 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Target sequencing by next generation sequencing (NGS), deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), troponin T, myosin light chain-1 (MLC-1), electrocardiogram, chest X-ray, exercise stress echocardiography, cardiac catheterization and magnetic resonance imaging (MRI).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Mol Med (Berl). 1998 Mar;76(3-4):208-14. [PMID: 9535554]
  • Circ J. 2019;83: 1908-1916. [PMID: 31308319]
  • Brain. 2013 Jan;136(Pt 1):282-93. [PMID: 23365102]
  • Heart Fail Rev. 2019;24: 439-459. [PMID: 30852773]
  • Cardiovasc Diagn Ther. 2019; 9: S388-S415. [PMID: 20869644]
  • Yale J Biol Med. 2017; 90: 433-448. [PMID: 28955182]
  • J Hum Genet. 2016;61: 41-50. [PMID: 26178429]
  • J Card Fail. 2012; 18: 296-303. [PMID: 22464770]
  • Post-genomic cardiology, in: cardiomyopathies: a comparative analysis of phenotypes and genotypes. 2014: 363-426. doi: 10.1016/b978-0-12-404599-6.00012-3
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login